Related Experiment Video
Updated: Mar 24, 2026
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Reversal of novel oral anticoagulants
Elsayed Abo-Salem1, Richard C Becker1
1Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Heart, Lung and Vascular Institute, Cincinnati, OH, USA.
Abstract:
The development of a new generation of non-vitamin K oral anticoagulants represents a potential breakthrough in the management of patients with thrombotic diseases, disorders and conditions. While a large and growing body of evidence from large-scale clinical trials and registries supports a favorable safety profile, having a means to rapidly reverse their anticoagulant effects represents an unmet need among practicing clinicians. Several targeted reversal agents are currently in development and the early results are promising. Idarucizumab is a monoclonal antibody that can immediately and specifically reverse dabigatran. Andexanet alfa is a recombinant modified factor Xa that can bind and reverse oral and parenteral factor Xa inhibitors, including rivaroxaban, apixaban and edoxaban, and low molecular weight heparin. Aripazine is a small molecule that can reverse the action of factor Xa inhibitors and possibly dabigatran as well through non-covalent binding and charge-charge interactions.
Insights
New reversal agents are emerging for non-vitamin K oral anticoagulants, addressing an unmet need for clinicians managing thrombotic diseases. These agents, including idarucizumab and andexanet alfa, show promising results in reversing anticoagulant effects.
Area of Science:
- Pharmacology
- Hematology
- Clinical Medicine
Background:
- Non-vitamin K oral anticoagulants (NOACs) offer advancements in managing thrombotic diseases.
- Existing NOACs have a generally favorable safety profile, but a need exists for rapid reversal agents.
- Clinicians require effective methods to quickly reverse anticoagulant effects in emergencies.
Purpose of the Study:
- To review the development and potential of targeted reversal agents for NOACs.
- To highlight specific agents and their mechanisms of action in reversing anticoagulation.
Main Methods:
- Review of clinical trials and registry data on NOAC safety.
- Description of emerging targeted reversal agents and their properties.
- Analysis of the mechanisms by which these agents reverse anticoagulation.
Main Results:
- Idarucizumab: A monoclonal antibody providing immediate and specific reversal of dabigatran.
- Andexanet alfa: A modified Factor Xa agent reversing oral/parenteral Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and heparin.
- Aripazine: A small molecule potentially reversing Factor Xa inhibitors and dabigatran.
Conclusions:
- Targeted reversal agents represent a significant advancement in managing patients on NOACs.
- These agents address the critical need for rapid reversal, enhancing patient safety.
- The development of idarucizumab, andexanet alfa, and aripazine offers promising solutions for clinical practice.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis IV: Nursing Management
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...